Oncotelic Therapeutics, Inc.
OTC:OTLC
Overview | Financials
Company Name | Oncotelic Therapeutics, Inc. |
Symbol | OTLC |
Currency | USD |
Price | 0.037 |
Market Cap | 14,731,883 |
Dividend Yield | 0% |
52-week-range | 0.01 - 0.09 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Vuong Trieu Ph.D. |
Website | https://www.oncotelic.com |
An error occurred while fetching data.
About Oncotelic Therapeutics, Inc.
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD